Apremilast is a potentially useful treatment for severe palmoplantar pustulosis with extra‐palmoplantar symptoms-Reference-Cited by-同舟云学术

Apremilast is a potentially useful treatment for severe palmoplantar pustulosis with extra‐palmoplantar symptoms

Published:2024-01-15 Issue: Volume: Page:
ISSN:2690-442X
Container-title:Skin Health and Disease
language:en
Short-container-title:Skin Health and Disease

Author:

Fukushima‐Nomura Ayano¹^ORCID,Takamiyagi Saeko¹,Kakuta Risa¹,Ito Yoshihiro¹,Hirai Ikuko¹,Umemoto Junichi²,Hanaoka Hironari³,Kaneko Yuko³,Tanese Keiji¹

Affiliation:

1. Department of Dermatology Keio University School of Medicine Tokyo Japan

2. Horinouchi‐ekimae Dermatology Clinic Yokohama Japan

3. Department of Rheumatology Keio University School of Medicine Tokyo Japan

Abstract

AbstractPalmoplantar pustulosis (PPP) is a chronic inflammatory skin disorder affecting the palms and soles. In rare cases, severe patients develop acute extra‐palmoplantar lesions often accompanied by arthralgia. Such cases with extensive symptoms often necessitate systemic treatments with variable efficacy and potential side effects. Apremilast, known for its broad immune response modulation, presents promise as a therapeutic option for severe PPP with joint and extra‐palmoplantar lesions. This case highlights apremilast as a potential systemic treatment for such cases with minimal side effects.

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ski2.336

Reference12 articles.

1. Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases

2. A multicentre open‐label study of apremilast in palmoplantar pustulosis (APLANTUS)

3. Efficacy of guselkumab in a subpopulation with pustulotic arthro‐osteitis through week 52: an exploratory analysis of a phase 3, randomized, double‐blind, placebo‐controlled study in Japanese patients with palmoplantar pustulosis